  Infection   Number of patients tested   Number of patients with reactive test   Prevalence (%)
  ----------- --------------------------- --------------------------------------- ----------------
  HIV         615                         297                                     48
  HCV         197                         6                                       3
  HBV         232                         15                                      6.5
  Syphilis    230                         45                                      19.6

![Median time since all OIs and non-TB OIs.](JIAS-18-20109-g001){#F0001_20109}

###### 

Baseline demographics and virologic responses

                                            GT 1 TN 24 weeks (*n*=226)   GT 2 TN 12 weeks (*n*=45)   GT 2 TE 24 weeks (*n*=30)   GT 3 TN 12 weeks (*n*=4)   GT 3 TN 24 weeks (*n*=57)   GT 3 TE 24 weeks (*n*=66)   GT 4 TN 24 weeks (*n*=31)
  ----------------------------------------- ---------------------------- --------------------------- --------------------------- -------------------------- --------------------------- --------------------------- ---------------------------
  Baseline characteristics                                                                                                                                                                                          
   Male, *n (*%)                            193 (85)                     36 (80)                     29 (97)                     34 (81)                    38 (67)                     52 (79)                     24 (77)
   Black, *n* (%)                           38 (17)                      6 (13)                      7 (23)                      2 (5)                      0                           1 (2)                       1 (3)
   IL28B CC genotype, *n* (%)               78 (35)                      22 (49)                     13 (43)                     15 (36)                    30 (53)                     25 (53)                     9 (29)
   Cirrhosis, *n* (%)                       22 (10)                      2 (4)                       6 (20)                      6 (14)                     3 (5)                       29 (44)                     8 (26)
   Log~10~ HCV RNA (IU/mL), mean (SD)       6.5 (0.8)                    6.6 (0.6)                   6.5 (0.8)                   6.6 (0.6)                  6.3 (0.7)                   6.3 (0.7)                   5.9 (0.9)
   CD4 T-cell count (cells/µL), mean (SD)   632 (265)                    573 (232)                   646 (314)                   559 (224)                  572 (268)                   600 (278)                   545 (208)
   On ART, *n* (%)                          221 (98)                     39 (87)                     29 (97)                     39 (93)                    57 (100)                    62 (94)                     30 (97)
   SVR12, *n/N* (%)                         181/226 (80)                 40/45 (89)                  27/30 (90)                  28/42 (67)                 52/57 (91)                  58/66 (88)                  26/31 (84)

###### 

Clinical findings of CHIKV infection in HIV-positive and HIV-negative cohorts

  Signs and symptoms                                 VIH (+) (%)   \% (95% CI)       VIH (--) (%)   \% (95% CI)        Odds (*p*)
  -------------------------------------------------- ------------- ----------------- -------------- ------------------ ---------------------
  Fever                                              48 (94.11)    (87.65--100%)     49 (100)       (100--100%)        0.1400 (*p*=0.1974)
  Headache                                           35 (68.62)    (55.88--81.36%)   37 (75.51)     (63.47--87.55%)    0.7095 (*p*=0.4444)
  Myalgia                                            48 (94.11)    (87.65--100%)     46 (93.87)     (87.15--100.59%)   1.0435 (*p*=0.9597)
  Upper limb arthralgia                              47 (92.15)    (84.77--99.53%)   47 (95.91)     (90.36--101.46%)   0.6667 (*p*=0.6648)
  Lower limb arthralgia                              47 (92.15)    (84.77--99.53%)   49 (100)       (100--100%)        0.1371 (*p*=0.1927)
  Arthritis                                          36 (70.58)    (58.07--83.09%)   38 (77.55)     (65.87--89.23%)    0.6947 (*p*=0.4286)
  Rash                                               37 (72.54)    (60.29--84.79%)   35 (71.42)     (58.77--84.07%)    0.9600 (*p*=0.9262)
  Nauseas                                            15 (29.41)    (16.91--41.91%)   24 (48.97)     (34.97--62.97%)    0.4340 (*p*=0.0467)
  Vomiting                                           9 (17.64)     (7.18--28.1%)     12 (24.48)     (12.44--36.52%)    0.6607 (*p*=0.4027)
  Diarrhoea                                          17 (33.33)    (20.39--46.27%)   17 (34.69)     (21.36--48.02%)    0.9412 (*p*=0.8858)
  Abdominal pain                                     21 (41.17)    (27.66--54.68%)   23 (46.93)     (32.96--60.9%)     0.7913 (*p*=0.5619)
  Others (pneumonia, encephalitis, Guillain-Barre)   16 (31.38)    (18.64--44.12%)   29 (59.18)     (45.42--72.94%)    0.3153 (*p*=0.0059)

![CHIKV specific IgM detection in HIV (−) and HIV (+) individuals after onset of symptoms, Dominican Republic 2014.](JIAS-18-20134-g001){#F0001_20134}

###### 

CHIKV IgM detection in HIV (+) and HIV (--) individuals, Dominican Republic 2014

                   HIV(+) *n*=51           HIV (--) *n*=49   
  ---------------- --------------- ------- ----------------- -------
  CHIKV IgM (+)    11              21.57   15                30.61
  CHIKV IgM (--)   40              78.43   34                69.39

![Data from the National System for Logistics Administration and Surveillance of ARV in Mexico (SALVAR) 31 of December, 2014. Database of the CIENI/CENSIDA, 2014. Database of the HIV Prison Programme in Mexico City 2014.](JIAS-18-20135-g001){#F0001_20135}

###### 

Virologic response rates during and after treatment

                                             12-week 3D + ribavirin (*N*=31)   24-week 3D + ribavirin (*N*=32)
  ------------------------------------------ --------------------------------- ---------------------------------------------------------------------------------------------------
  Response, *n* (%) \[95% CI\]                                                 
   RVR                                       31 (100) \[89--100\]              32 (100) \[89--100\]
   EOTR                                      30 (97) \[84--99\]                31 (97) \[84--100\]
   SVR12                                     29 (94) \[79--98\]                29 (91) \[76--97\][a](#TF0001_20142){ref-type="table-fn"},[b](#TF0002_20142){ref-type="table-fn"}
   SVR24                                     29 (94) \[79--98\]                29 (91) \[76--97\][a](#TF0001_20142){ref-type="table-fn"},[b](#TF0002_20142){ref-type="table-fn"}
  Reasons for not achieving SVR12, *n* (%)                                     
   Early study discontinuation               1 (3)                             0
   Virologic breakthrough during treatment   0                                 1 (3)
   Virologic relapse after treatment         1 (3)                             0
   HCV re-infection after treatment          0                                 2 (6)[a](#TF0001_20142){ref-type="table-fn"},[b](#TF0002_20142){ref-type="table-fn"}

Denotes one patient with HCV re-infection at post-treatment week 8

denotes one patient with HCV re-infection at post-treatment week 12.

Ninety-five percent confidence intervals calculated using the Wilson score method for the binomial distribution.

3D, ombitasvir/paritaprevir/r and dasabuvir; RVR, rapid virologic response; EOTR, end of treatment response; SVR12, sustained virologic response at post-treatment week 12; SVR24, sustained virologic response at post-treatment week 24.

###### 

Abstract P019

                                                                         Whole population *n*=996   20--29 *n*=244      30--39 *n*=417      40--49 *n*=238      ≥0 *n*=97
  ---------------------------------------------------------------------- -------------------------- ------------------- ------------------- ------------------- -------------------
  Hypercholesterolemia[\*](#TF0001_20150){ref-type="table-fn"}           25.8 (23.1--28.5)          16.8 (12.1--21.5)   21.3 (17.4--25.3)   33.6 (27.6--39.7)   48.5 (38.3--58.6)
  Hypertriglyceridemia[\*](#TF0001_20150){ref-type="table-fn"}           59.1 (56.1--62.2)          39.8 (33.6--45.9)   59.5 (54.7--64.2)   70.2 (64.3--76.0)   79.4 (71.2--87.6)
  Diabetes Mellitus[\*](#TF0001_20150){ref-type="table-fn"}              3.2 (2.1--4.3)             0.0                 1.7 (0.4--2.9)      7.1 (3.8--10.4)     8.3 (2.7--13.8)
  High blood pressure[\*](#TF0001_20150){ref-type="table-fn"}            11.1 (9.2--13.1)           6.6 (3.4--9.7)      7.7 (5.1--10.2)     16.8 (12.0--21.6)   23.7 (15.1--32.3)
  Smoking[\*](#TF0001_20150){ref-type="table-fn"}                        42.1 (39.0--45.1)          47.1 (40.8--53.4)   45.3 (40.5--50.1)   36.1 (30.0--42.3)   29.9 (20.6--39.2)
  Nutritional status                                                                                                                                            
   Overweight (25\<30 kg/m^2^)[\*](#TF0001_20150){ref-type="table-fn"}   36.4 (33.4--39.3)          20.1 (15.1--25.1)   37.9 (33.2--42.6)   48.3 (41.9--54.7)   41.2 (31.3--51.2)
   Obesity (≥30 kg/m^2^)[\*](#TF0001_20150){ref-type="table-fn"}         7.7 (6.1--9.4)             5.7 (2.8--8.7)      6.0 (3.7--8.3)      10.9 (6.9--14.9)    12.4 (5.7--19.0)
  Framingham                                                                                                                                                    
   Moderate (5\<10%)[\*](#TF0001_20150){ref-type="table-fn"}             23.6 (21.0--26.2)          5.7 (2.8--8.7)      19.4 (15.6--23.2)   44.1 (37.8--50.5)   36.1 (26.4--45.8)
   High (10\<15%)[\*](#TF0001_20150){ref-type="table-fn"}                7.0 (5.6--9.0)             0.0                 2.9 (1.3--4.5)      12.6 (8.4--16.9)    28.9 (19.7--38.0)
   Very high (≥15%)[\*](#TF0001_20150){ref-type="table-fn"}              3.3 (2.2--4.4)             0.0                 0.2 (0.0--1.3)      2.9 (0.8--5.1)      25.8 (16.9--34.6)

Data are presented as percentages.

*p\<*0.05.

  Death cause                              Pre-HAART (%)   Partial use of HAART (%)   HAART (%)
  ---------------------------------------- --------------- -------------------------- -----------
  AIDS defining illness                    63.9            71.1                       51
  Non-opportunistic infections             21.1            17.1                       28.3
  Chronic hepatic disease decompensation   4.5             5.9                        12.6
  AIDS non-defining tumour                 0               0.7                        3.5
  Others                                   10.5            5.3                        4.6

###### 

Psychometric properties of SIS

  Factor (items)                Mean score (0--3 rank)   Cronbach\'s α   Explained variance (%)   Item-total correlations   Factorial congruence coefficients
  ----------------------------- ------------------------ --------------- ------------------------ ------------------------- -----------------------------------
  Automatism attentional (12)   1.44                     0.91            42.1                     0.52--0.75                0.708--0.971
  Gratification (5)             0.65                     0.81            6.9                      0.40--0.69                0.598--0831
  SIS total                                              0.92            49.0                                               

![E/C/F/TAF in adolescents: virologic success and CD4 recovery.](JIAS-18-20157-g001){#F0001_20157}

###### 

Summary of efficacy outcomes for overall and LA population at Week 48

  Overall SAILING population \[[@CIT0001_20163]\]                                                                                              DTG 50 mg once daily, *N=*354      RAL 400 mg BID, *N=*361
  -------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ----------------------------
  Number of responders at Week 48 (HIV-1 RNA\<50 c/ml), *n/N* (%)                                                                              251/354 (71)                       230/361 (64)
  Adjusted difference in proportion (95% CI) (DTG-RAL)                                                                                         7.4 (0.7, 14.2)                    
  Cochran-mantel-haenszel *P*-value                                                                                                            0.030                              
  **Latin America subgroup**                                                                                                                   **DTG 50 mg once daily *N=*123**   **RAL 400 mg BID *N=*115**
  Baseline HIV-1 RNA log~10~ c/ml, median (range)                                                                                              4.17 (1.59, 6.16)                  4.22 (1.59, 6.54)
  Baseline CDC class C category, *n* (%)                                                                                                       70 (57)                            51 (44)
  Number of responders at Week 48 (HIV-1 RNA\<50 c/ml), *n/N* (%)                                                                              91/123 (74)                        78/115 (68)
  Adjusted difference in proportion (95% CI) (DTG-RAL)                                                                                         6.3 (−5.0, 17.7)                   
  Proportion (%) of subjects without treatment-related failure (TRDF), Kaplan-Meier estimate (95% CI)[a](#TF0001_20163){ref-type="table-fn"}   92.4 (86.0, 96.0)                  81.9 (73.4, 87.9)
  Difference in proportion (95% CI) (DTG-RAL)                                                                                                  10.5 (1.9, 19.1)                   

Treatment-related discontinuation equals failure (TRDF): protocol-defined virologic failure or withdrawal due to drug-related adverse event, safety stopping criteria; HIV-1 RNA greater than 50 c/ml not regarded as failure unless criteria for protocol-defined virologic failure were met.
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